Stock CCCC C4 THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials C4 Therapeutics, Inc.

Equities

CCCC

US12529R1077

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
6.17 USD -1.12% Intraday chart for C4 Therapeutics, Inc. -8.18% +9.20%
04-08 C4 Therapeutics, Inc. Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024 CI
03-18 C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to S&P Biotechnology Select Industry Index CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,426 1,566 288.8 278.4 423.3 - -
Enterprise Value (EV) 1 1,064 1,500 21.89 24.76 169.2 179.7 138.4
P/E ratio -21.5 x -17.7 x -2.25 x -2.12 x -3.2 x -3.1 x -4.6 x
Yield - - - - - - -
Capitalization / Revenue 42.9 x 34.2 x 9.29 x 13.4 x 16.1 x 19.9 x 4.02 x
EV / Revenue 32.1 x 32.8 x 0.7 x 1.19 x 6.42 x 8.46 x 1.32 x
EV / EBITDA -19.2 x -25.4 x -0.22 x -0.23 x -1.9 x -2.07 x -3.62 x
EV / FCF -15.7 x -17 x -0.2 x -0.23 x -1.36 x -1.25 x -0.88 x
FCF Yield -6.38% -5.88% -509% -438% -73.4% -79.9% -114%
Price to Book 5.08 x 4.02 x 1 x 1.39 x 1.93 x 3.59 x 2.12 x
Nbr of stocks (in thousands) 43,030 48,626 48,957 49,281 68,601 - -
Reference price 2 33.13 32.20 5.900 5.650 6.170 6.170 6.170
Announcement Date 21-03-11 22-02-24 23-02-23 24-02-22 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 21.38 33.2 45.78 31.1 20.76 26.34 21.24 105.2
EBITDA 1 - -55.4 -59.13 -97.84 -109.9 -89.14 -86.84 -38.19
EBIT 1 - -60.45 -82.13 -129.5 -139 -133.8 -148.2 -133.6
Operating Margin - -182.1% -179.39% -416.56% -669.84% -508.09% -697.75% -126.95%
Earnings before Tax (EBT) 1 - -66.96 -83.89 -128.2 -131.2 -131.8 -155.5 -124.8
Net income 1 - -66.34 -83.89 -128.2 -132.5 -139.5 -154.3 -132.4
Net margin - -199.83% -183.23% -412.19% -638.34% -529.61% -726.37% -125.88%
EPS 2 -3.670 -1.542 -1.820 -2.620 -2.670 -1.931 -1.993 -1.342
Free Cash Flow 1 - -67.9 -88.24 -111.4 -108.5 -124.2 -143.7 -157.8
FCF margin - -204.55% -192.73% -358.36% -522.96% -471.57% -676.46% -149.95%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 20-09-10 21-03-11 22-02-24 23-02-23 24-02-22 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 8.5 20.08 7.654 13.83 6.754 2.854 3.759 2.664 11.07 3.261 9.283 3.883 6.417 3.7 -
EBITDA 1 -23.92 -8.579 -31.06 -26.95 -32.07 -30.85 -35.68 -30.68 -27.36 -30.64 -18.26 -23.31 -20.65 -23.75 -
EBIT 1 -24.25 -15.26 -31.37 -27.38 -32.49 -38.29 -36.23 -37.57 -27.81 -37.43 -27.12 -32.43 -30.5 -35.96 -
Operating Margin -285.34% -75.98% -409.84% -197.95% -481.02% -1,341.73% -963.77% -1,410.21% -251.16% -1,147.72% -292.08% -835.04% -475.26% -971.78% -
Earnings before Tax (EBT) 1 -24.68 -15.66 -31.62 -27.41 -31.96 -37.18 -34.78 -35.92 -26.03 -34.48 -24.45 -31.35 -29.1 -35.38 -
Net income 1 -24.68 -15.66 -31.62 -27.41 -31.96 -37.18 -34.78 -35.92 -27.04 -34.75 -27.08 -33 -31.83 -36.56 -
Net margin -290.39% -77.99% -413.12% -198.15% -473.17% -1,302.91% -925.25% -1,348.42% -244.19% -1,065.75% -291.74% -849.69% -496.12% -988% -
EPS 2 -0.5100 -0.3100 -0.6500 -0.5600 -0.6500 -0.7600 -0.7100 -0.7300 -0.5500 -0.6800 -0.4120 -0.4887 -0.4689 -0.4854 -
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 21-11-10 22-02-24 22-05-05 22-08-04 22-11-03 23-02-23 23-05-04 23-08-08 23-11-01 24-02-22 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - 362 65.4 267 254 254 244 285
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - -67.9 -88.2 -111 -109 -124 -144 -158
ROE (net income / shareholders' equity) - - -25% -37.8% -49.5% -42.5% -62.1% -60.1%
ROA (Net income/ Total Assets) - - -18.5% -27.3% -32.8% -35.5% -80.8% -49.6%
Assets 1 - - 453.5 468.8 403.6 393.3 191 267.1
Book Value Per Share 2 - 6.520 8.000 5.920 4.070 3.210 1.720 2.910
Cash Flow per Share 2 - - -1.890 -2.170 -2.150 -0.3800 -2.620 -0.3200
Capex 1 - 0.65 1.28 5.5 1.71 2.33 3.23 3.78
Capex / Sales - 1.96% 2.79% 17.67% 8.23% 8.85% 15.2% 3.6%
Announcement Date 20-09-10 21-03-11 22-02-24 23-02-23 24-02-22 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for C4 Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.17 USD
Average target price
17.22 USD
Spread / Average Target
+179.13%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
C4 THERAPEUTICS, INC. Stock C4 Therapeutics, Inc.
+9.20% 423M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CCCC Stock
  4. Financials C4 Therapeutics, Inc.